Abstract #1232

Combined 18-FET-PET and diffusion kurtosis imaging study in treated glioblastoma patients: differentiation between metabolically active tumours and treatment-induced tissue abnormalities

Farida Grinberg^1,2, Francesco D’Amore¹, Jörg Mauler¹, Norbert Galldiks^3,4,5, Ezequiel Farrher¹, Ganna Blazhenets¹, Gabriele Stoffels¹, N. Jon Shah^1,2,6, and Karl-Josef Langen^1,5,6

¹Institute of Neuroscience and Medicine 4, Research Centre Juelich, Juelich, Germany, ²Department of Neurology, Faculty of Medicine, RWTH Aachen University, Aachen, Germany, ³Institute of Neuroscience and Medicine 3, Forschungszentrum Juelich, Jülich, Germany, ⁴Department of Neurology, University Hospital Cologne, Cologne, Germany, ⁵Center of Integrated Oncology (CIO), Universities of Cologne and Bonn, Cologne, Germany, ⁶JARA - BRAIN - Translational Medicine, RWTH Aachen University, Aachen, Germany

MRI and diffusion MRI techniques provide important diagnostic information regarding anatomic structure and microstructural features in brain tumours with high spatial resolution. 18F-FET-PET enables identification of the metabolically active regions in spatially heterogeneous lesions, information lacking in any MRI techniques. In this work we report a novel approach combining metabolic information gained from PET and microstructural information obtained from diffusion kurtosis histogram analysis. This approach was shown to provide sensitive biomarkers allowing for differentiation between progressing tumours and treatment-induced tissue abnormalities in glioblastoma patients. *The first two authors contributed equally to the work.

This abstract and the presentation materials are available to members only; a login is required.

Join Here